<DOC>
	<DOCNO>NCT01490086</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety RP5063 relative placebo treatment schizophrenia schizoaffective disorder .</brief_summary>
	<brief_title>RP5063 Subjects With Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Patients provide informed consent prior study specific procedure Patients meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion schizophrenia ( paranoid type , disorganize type , catatonic type undifferentiated type ) , schizoaffective disorder Patients normal physical examination , laboratory , vital sign , electrocardiogram ( ECG ) Patients primary psychiatric disorder delirium , bipolar I II disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>